Use of polypeptides with calcium indicator activity for identifying the activity of insecticidal proteins
US-2024426834-A1 · Dec 26, 2024 · US
Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
US9157906B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9157906-B2 |
| Application number | US-95177510-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 22, 2010 |
| Priority date | Aug 31, 2001 |
| Publication date | Oct 13, 2015 |
| Grant date | Oct 13, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides methods and compositions for modulating the activity of phosphodiesterase 1B (PDE1B) in intracellular signaling pathways, including but not limited to, dopamine D1 intracellular signaling pathways. The invention also provides methods and compositions for modulating the activities of intracellular signaling molecules, including, but not limited to, DARPP-32 and GluR1 AMPA receptor, via modulation of PDE1B. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate PDE1B activity. The invention also provides methods of treating or ameliorating the symptoms of a disorder, including but not limited to a PDE1B-related disorder or a dopamine D1 receptor intracellular signaling pathway disorder, by administering a modulator of PDE1B, preferably, but not limited to, an inhibitor of PDE1B or an agent that decreases the production of PDE1B.
First claim
Opening claim text (preview).
What is claimed is: 1. An in vitro method of identifying a compound that inhibits phosphodiesterase 1 B (“PDE1B”) activity in a dopamine D1 receptor intracellular signaling pathway by binding to or altering the expression of PDE1B in a cell or tissue expressing dopamine D1 receptor comprising: (a) determining a first level of PDE1B activity and Thr34 of DARPP-32 phosphorylation in said cell or tissue; (b) contacting said cell or tissue with a test compound; and (c) determini…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9157906B2 cover?
- The present invention provides methods and compositions for modulating the activity of phosphodiesterase 1B (PDE1B) in intracellular signaling pathways, including but not limited to, dopamine D1 intracellular signaling pathways. The invention also provides methods and compositions for modulating the activities of intracellular signaling molecules, including, but not limited to, DARPP-32 and Glu…
- Who is the assignee on this patent?
- Greengard Paul, Repaske David, Snyder Gretchen, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5041. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Oct 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).